Upstream Bio Inc (UPB)

$8.95 -0.16 (-1.76%)
Market Cap 495.77M
Revenue (ttm) 2.85M
Net Income (ttm) -143.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,032.98%
Debt to Equity Ratio 0.00
Volume 467,500
Avg Vol 732,636
Day's Range N/A - N/A
Shares Out 54.42M
Stochastic %K 29%
Beta 1.28
Analysts Strong Sell
Price Target $43.50

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
Eliteh
Eliteh May. 12 at 5:43 PM
$UPB should see $7S and lower soon 🙏. Will buy a lot then
0 · Reply
SuperGreenToday
SuperGreenToday May. 8 at 3:08 AM
$UPB Share Price: $8.99 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.45 – $1.77 Potential Upside: 61% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Eliteh
Eliteh May. 7 at 4:09 PM
$UPB keeping an eye as this looks like it'll drop off a cliff and give a great buying opportunity. Bearish for now
0 · Reply
Eliteh
Eliteh May. 5 at 5:21 PM
$UPB Will revisit in low $8S or less
0 · Reply
Eliteh
Eliteh May. 5 at 4:40 PM
$UPB I've sold - this stock is dead in the water, unfortunately. Seems like they're pulling from their $150M ATM and have no catalysts soon. Best of luck everyone!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 28 at 8:31 PM
$UPB RSI: 45.27, MACD: -0.2482 Vol: 0.42, MA20: 9.76, MA50: 8.97 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 27 at 5:57 PM
$UPB Current Stock Price: $9.27 Contracts to trade: $10.0 UPB May 15 2026 Call Entry: $0.32 Exit: $0.60 ROI: 91% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Cheaslea76
Cheaslea76 Apr. 16 at 10:05 AM
$UPB earning 26th March
1 · Reply
bababooey143
bababooey143 Apr. 15 at 2:44 PM
$UPB I'm out no volume
0 · Reply
theBigDollarski
theBigDollarski Apr. 15 at 10:18 AM
$UPB r
0 · Reply
Latest News on UPB
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

2026-04-17T11:07:21.000Z - 26 days ago

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Apr 17, 2026, 7:00 AM EDT - 26 days ago

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

2026-03-27T10:45:28.000Z - 6 weeks ago

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 7:00 AM EDT - 6 weeks ago

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:40 PM EDT - 2 months ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 2 months ago

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

Upstream Bio announces verekitug met the primary endpoint

2026-03-01T16:35:25.000Z - 2 months ago

Upstream Bio announces verekitug met the primary endpoint

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Mar 1, 2026, 9:45 AM EST - 2 months ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 26, 2026, 7:00 AM EST - 2 months ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 7:00 AM EST - 2 months ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio Transcript: Study result

Feb 11, 2026, 8:00 AM EST - 3 months ago

Upstream Bio Transcript: Study result

Upstream Bio reports results from Phase 2 VALIANT clinical trial

2026-02-11T11:15:40.000Z - 3 months ago

Upstream Bio reports results from Phase 2 VALIANT clinical trial

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 11, 2026, 6:00 AM EST - 3 months ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Feb 10, 2026, 6:00 PM EST - 3 months ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio management to meet virtually with Piper Sandler

2026-01-20T19:55:30.000Z - 4 months ago

Upstream Bio management to meet virtually with Piper Sandler

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 4 months ago

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 4 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio initiated with an Outperform at Mizuho

2025-12-17T21:16:04.000Z - 5 months ago

Upstream Bio initiated with an Outperform at Mizuho

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:25 AM EST - 5 months ago

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 4:30 PM EST - 5 months ago

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Upstream Bio initiated with an Outperform at LifeSci Capital

2025-12-02T12:15:17.000Z - 5 months ago

Upstream Bio initiated with an Outperform at LifeSci Capital

Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 25, 2025, 7:00 AM EST - 6 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio initiated with an Outperform at Evercore ISI

2025-11-18T09:55:15.000Z - 6 months ago

Upstream Bio initiated with an Outperform at Evercore ISI

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 10:30 AM EST - 6 months ago

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 9:20 AM EST - 6 months ago

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

Upstream Bio files automatic mixed securities shelf

2025-11-05T12:40:50.000Z - 6 months ago

Upstream Bio files automatic mixed securities shelf

Upstream Bio reports Q3 revenue $683k, consensus $516.8k

2025-11-05T12:22:15.000Z - 6 months ago

Upstream Bio reports Q3 revenue $683k, consensus $516.8k

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Nov 5, 2025, 7:00 AM EST - 6 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio to Participate in Upcoming November Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 6 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio initiated with a Buy at Truist

2025-10-14T10:15:42.000Z - 7 months ago

Upstream Bio initiated with a Buy at Truist

Upstream Bio management to meet with Piper Sandler

2025-10-07T19:30:14.000Z - 7 months ago

Upstream Bio management to meet with Piper Sandler

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 30, 2025, 4:15 AM EDT - 8 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 15, 2025, 10:30 AM EDT - 8 months ago

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 8 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Transcript: Study Update

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Upstream Bio Transcript: Study Update

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 2, 2025, 6:00 AM EDT - 9 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 9 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 15, 2025, 7:45 AM EDT - 11 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 5:15 PM EST - 1 year ago

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:00 PM EST - 1 year ago

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Eliteh
Eliteh May. 12 at 5:43 PM
$UPB should see $7S and lower soon 🙏. Will buy a lot then
0 · Reply
SuperGreenToday
SuperGreenToday May. 8 at 3:08 AM
$UPB Share Price: $8.99 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.45 – $1.77 Potential Upside: 61% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Eliteh
Eliteh May. 7 at 4:09 PM
$UPB keeping an eye as this looks like it'll drop off a cliff and give a great buying opportunity. Bearish for now
0 · Reply
Eliteh
Eliteh May. 5 at 5:21 PM
$UPB Will revisit in low $8S or less
0 · Reply
Eliteh
Eliteh May. 5 at 4:40 PM
$UPB I've sold - this stock is dead in the water, unfortunately. Seems like they're pulling from their $150M ATM and have no catalysts soon. Best of luck everyone!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 28 at 8:31 PM
$UPB RSI: 45.27, MACD: -0.2482 Vol: 0.42, MA20: 9.76, MA50: 8.97 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 27 at 5:57 PM
$UPB Current Stock Price: $9.27 Contracts to trade: $10.0 UPB May 15 2026 Call Entry: $0.32 Exit: $0.60 ROI: 91% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Cheaslea76
Cheaslea76 Apr. 16 at 10:05 AM
$UPB earning 26th March
1 · Reply
bababooey143
bababooey143 Apr. 15 at 2:44 PM
$UPB I'm out no volume
0 · Reply
theBigDollarski
theBigDollarski Apr. 15 at 10:18 AM
$UPB r
0 · Reply
bababooey143
bababooey143 Apr. 11 at 9:39 PM
$UPB
0 · Reply
bababooey143
bababooey143 Apr. 11 at 9:39 PM
$UPB it's says 10.80 on webull but 10.29 here?
0 · Reply
bababooey143
bababooey143 Apr. 9 at 9:40 PM
$UPB
0 · Reply
theBigDollarski
theBigDollarski Apr. 9 at 7:24 PM
$UPB
0 · Reply
StockConsultant
StockConsultant Mar. 26 at 2:26 PM
$UPB Upstream Bio stock, nice bottom breakout, from Stocks to Watch at https://stockconsultant.com/?UPB
0 · Reply
nikserr
nikserr Mar. 26 at 2:23 PM
$UPB I am out of UPB for now, I may get back in if it pulls back.
0 · Reply
nikserr
nikserr Mar. 26 at 2:02 PM
$UPB 32% Gain in no time !!
0 · Reply
nikserr
nikserr Mar. 26 at 1:57 PM
$UPB this happened in no time :)) My followers have made so much money already $JANX
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 26 at 12:18 PM
$UPB (+2.4% pre) Upstream Bio plans two late-stage trials for asthma, nasal polyps in 2027 https://ooc.bz/l/97306
0 · Reply
Jamminonfools
Jamminonfools Mar. 20 at 9:00 PM
$UPB anybody know why this jump up around .50 right before close?
0 · Reply
jd39
jd39 Mar. 19 at 1:29 PM
$UPB or maybe US$ 9
0 · Reply
Off_The_Top_Rope
Off_The_Top_Rope Mar. 18 at 9:24 PM
$UPB $12
0 · Reply